Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 17, Issue 4, 1998, Pages 339-344

  Lalezari, Jacob P ^a,r   Holland, Gary N ^b   Kramer, Françoise ^c   McKinley, George F ^d   Kemper, Carol A ^e   Ives, David V ^f   Nelson, Robert ^g   David Hardy, W ^h   Kuppermann, Baruch D ⁱ   Northfelt, Donald W ^j   Youle, Michael ^k   Johnson, Margaret ^l   Lewis, Richard Alan ^m   Weinberg, David V ⁿ   Simon, Gary L ^o   Wolitz, Richard A ^p   Ruby, April E ^q   Stagg, Robert J ^q   Jaffe, Howard S ^q  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JULES STEIN EYE INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Howard Hughes Medical Institute   (United States)

^e SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k Kobler Centre   (United Kingdom)

^l ROYAL FREE HOSPITAL   (United Kingdom)

^m BAYLOR COLLEGE OF MEDICINE   (United States)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

^o GEORGE WASHINGTON UNIVERSITY   (United States)

^p KAISER PERMANENTE   (United States)

^q GILEAD SCIENCES   (United States)

^r Quest Clinical Research   (United States)

more..

Author keywords

AIDS; Cidofovir; CMV retinitis

Indexed keywords

CIDOFOVIR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSCARNET; GANCICLOVIR; PROBENECID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RETINITIS; TREATMENT OUTCOME; VISUAL ACUITY;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 13144262846     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199804010-00008     Document Type: Article

References (23)

1. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993; 329:1922-6.
2. + counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993;115:575-82.
3. Holland GN, Pepose JS, Pettit TH, et al. Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology 1983;90: 859-73.
4. Pepose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY. Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology 1985;92:472-84.
5. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989;107: 75-80.
6. De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res 1987;8:261-72.
7. Snoeck R, Sakuma T, De Clercq E, Rosenberg I, Holy A. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine: a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 1988;32:1839-44.
8. Bronson JJ, Ghazzouli I, Hitchcock MJM, Webb RR, Martin JC. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. J Med Chem 1989;32:1457-63.
9. Kedes DH, Ganem, D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. J Clin Invest 1997;99: 2082-6.
10. Snoeck R, Andrei G, DeCercq E, et al. A new topical treatment for resistant herpes simplex infections [letter]. N Engl J Med 1993; 329:968-9.
11. Lalezari JP, Drew WL, Glutzer E, et al. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 1994;170:570-2.
12. Biron KK, Stanet SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-[2-hydroxy-1-(hydroxymethy)ethoxy]-methylguanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci USA 1985;82:2473-7.
13. Ho HT, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJM. Intracellular metabolism of the antiherpes agent (S)-1-(3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 1991;41:197-202.
14. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995;171:788-96.
15. Polis MA, Spooner KM, Baird BF, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 1995;39:882-6.
16. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1997;126:257-63.
17. Studies of the Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Ann Intern Med 1997;126:264-74.
18. Karnofsky DA, Abelmann NH, Craver CF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-56.
19. Kernhauser DM, Petty BG, Hendrix CW, et al. Probenecid and zidovudine metabolism. Lancet 1989;2:473-5.
20. Altman DG. Practical statistics for medical research. New York: Chapman and Hall, 1991.
21. Studies of the Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326: 213-20.
22. Studies of the Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med 1995;155:65-74.
23. Studies of the Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Foscarnet - ganciclovir cytomegalovirus retinitis trial 4: visual outcomes. Ophthalmology 1994;101: 1250-61.